VANCOUVER HOSPITAL & HEALTH SCIENCES CENTRE
CSU PHARMACEUTICAL SCIENCES
SPECIAL ACCESS DRUG DATA SHEET

DRUG NAME
Rifampin Sodium

ALTERNATE NAME
Rifadine®, rifampicine

MANUFACTURER
sanofi aventis

STRENGTH
600 mg vial as powder for reconstitution

DOSAGE FORM
Injection

INDICATIONS
- In combination with other agents in treatment of tuberculosis and other mycobacterial diseases when oral route is not feasible

DOSAGE AND ADMINISTRATION
- Dosage
  - Tuberculosis and other mycobacterial disease:
    - Adults: 600 mg IV daily
    - Infants < 1 week of age: maximum 10 mg/kg/day
    - Infants old > 1 week and children: 10-20 mg/kg/day
  - Dosage adjustment not required in renal failure or during peritoneal dialysis or hemodialysis

- Reconstitution
  - Reconstitute contents of vial with 10mL of the provided solution for reconstitution. Final concentration of 60mg/mL is stable for 24 hours at room temperature.
  - Swirl vial gently until contents are completely dissolved
  - Dilute each 600 mg in at least 250mL of compatible infusion solution and infuse over 3 hours
  - Stability in normal saline = 24 hrs and in D5W = 4 hrs; store at room temperature. Dilution in other infusion solutions is not recommended.
  - Alternatively, the appropriate dose may be added to 100 mL of compatible solution and infused over 30 minutes
  - Store unreconstituted powder at room temperature

KNOWN SIDE EFFECTS*
- GI disturbances include: heartburn, epigastric distress, nausea, vomiting, anorexia, diarrhea
- Headache, drowsiness, mental confusion, pains in muscles and joints have also occurred, especially during the first few weeks of therapy pain and swelling at injection site; thrombophlebitis after prolonged use
- Abnormal liver function tests

SPECIAL PRECAUTIONS
- Incompatible with 5% sodium bicarbonate solution
- Incompatible with other drugs
- Hepatitis and jaundice have been reported in patients with pre-existing liver disease, or those receiving concomitant hepatotoxic drugs
- High intermittent doses may cause shortness of breath, wheezing, hypotension and shock
- If local irritation and inflammation due to extravascular infiltration of the infusion, discontinue the infusion and restart at another site
- Do not administer by IM or SC routes

*** REPORT ANY ADVERSE DRUG REACTIONS TO THE PHARMACY**